Akanda Corp.(AKAN)

Drug Manufacturers - Specialty & Generic · Toronto, ON

$1.92+0.01 (+0.27%)

Delayed quote: Oct 6, 2026, 12:22 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T16:25:37.215Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:25:37.215Z.

Quote observation: 2026-10-06T16:22:53.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 61,984
Total debt · period ending 2026-06-30: 18,570,827
Cash · period ending 2026-06-30: 755,238
TTM operating EBITDA · period ending 2026-06-30: N/A

FMP input reference: 76b909c1583fef9061a4d716d1bfa7e8c39158eca830282836b9decd9e758125

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

AKAN EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

AKAN Competitors' EV/EBITDA Ratio

AKAN

Akanda Corp.

Current

Market Cap

$61984.00

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PRFX

PRF Technologies Ltd.

vs AKAN

Market Cap

$70876.00

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MNDR

Mobile-health Network Solutions Class A Ordinary Shares

vs AKAN

Market Cap

$30755.00

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PBM

Psyence Biomedical Ltd.

vs AKAN

Market Cap

$93421.00

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NIVF

NewGenIvf Group Limited

vs AKAN

Market Cap

$6172.00

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NIKI

Niki BioSolutions, Inc.

vs AKAN

Market Cap

$381940.00

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HCWB

HCW Biologics Inc.

vs AKAN

Market Cap

$559702.00

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CDT

CDT Equity Inc.

vs AKAN

Market Cap

$680476.00

EV/EBITDA Ratio

4.13x

TTM Avg

10.27x

3Y Avg

9.51x

5Y Avg

9.51x

RDGT

Ridgetech, Inc.

vs AKAN

Market Cap

$809925.00

EV/EBITDA Ratio

N/A

TTM Avg

21.16x

3Y Avg

12.50x

5Y Avg

7.56x

BJDX

Bluejay Diagnostics, Inc.

vs AKAN

Market Cap

$822494.00

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Akanda Corp. (AKAN)	$61984.00	N/A	N/A	N/A	N/A
PRF Technologies Ltd. (PRFX)vs ›	$70876.00	N/A	N/A	N/A	N/A
Mobile-health Network Solutions Class A Ordinary Shares (MNDR)vs ›	$30755.00	N/A	N/A	N/A	N/A
Psyence Biomedical Ltd. (PBM)vs ›	$93421.00	N/A	N/A	N/A	N/A
NewGenIvf Group Limited (NIVF)vs ›	$6172.00	N/A	N/A	N/A	N/A
Niki BioSolutions, Inc. (NIKI)vs ›	$381940.00	N/A	N/A	N/A	N/A
HCW Biologics Inc. (HCWB)vs ›	$559702.00	N/A	N/A	N/A	N/A
CDT Equity Inc. (CDT)vs ›	$680476.00	4.13x	10.27x	9.51x	9.51x
Ridgetech, Inc. (RDGT)vs ›	$809925.00	N/A	21.16x	12.50x	7.56x
Bluejay Diagnostics, Inc. (BJDX)vs ›	$822494.00	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics